Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3530638 | 0.91 | SLC6A4 (0.43) | SLC6A3JAK2JAK1SLC6A4SLC6A2 | |
| SCHEMBL30479381 | 0.84 | JAK2 (0.46) | JAK2JAK1TACR1 | |
| SCHEMBL3528223 | 0.84 | JAK2 (0.46) | JAK2JAK1TACR1 | |
| SCHEMBL21680273 | 0.83 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2AKR1C3AKR1C2 | |
| SCHEMBL16565154 | 0.83 | OPRM1 (0.48) | SLC6A3JAK2JAK1SLC6A4SLC6A2 | |
| SCHEMBL3528089 | 0.82 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2AKR1C3AKR1C2 | |
| SCHEMBL17886631 | 0.80 | SLC6A3 (0.44) | SLC6A3JAK2JAK1SLC6A4SLC6A2 | |
| SCHEMBL6153201 | 0.80 | METAP2 (0.38) | CYP3A4CYP2C19 | |
| SCHEMBL27640138 | 0.79 | JAK2 (0.41) | SLC6A3JAK2JAK1SLC6A4SLC6A2 | |
| SCHEMBL5381232 | 0.78 | CCR1 (0.50) | SLC6A3AKR1C3AKR1C2APPCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3532462-B1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-02-13 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836758-B2 | Acyl sulfonamide NaV1.7 inhibitors | SCN7A, SCN1A, SCN8A | SLC6A3 298/4885JAK2 3928/4885JAK1 4552/4885 |
| US-20200048240-A1 | ACYL SULFONAMIDE NAV1.7 INHIBITORS | SCN7A, SCN1A, SCN8A | SLC6A3 298/4885JAK2 3928/4885JAK1 4552/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | SLC6A3 1496/4885JAK2 2862/4885JAK1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.